Publication
Article
Pharmacy Times
With time running outfor the 2007 session ofthe 110th Congress,Generic PharmaceuticalAssociation (GPhA) leaderscalled on lawmakers to step up efforts to enact legislationthat would streamline the approval of lower-cost genericversions of biological products. ?For the countlessAmericans who are in need of safe and affordable lifesavingbiogenerics, it is imperative that Congress continue to movelegislation forward,? GPhA President and Chief ExecutiveOfficer Kathleen Jaeger said during the association?s AnnualPolicy Conference in Washington. ?We?ve come a long way ina short period of time, but we still need to cross the finishline.?
The bill supported by GPhA has also drawn backing frommore than 70 other organizations that consider it importantto lower the cost of biologicals. If the bill fails to clear the currentCongress before adjournment, the issue could emergeas a priority for candidates during next fall?s national elections.